NCT04816175

Intensive Therapy for Children With Microcephaly, Hyperkinetic Movements, or Global Developmental Delay

Completed NA Last updated 13 October 2022

What this trial tests

NA trial testing Acquire Therapy in Microcephaly in 4 participants. Completed in 11 August 2022.

Timeline

30 April 2019

Primary endpoint
30 December 2021

11 August 2022

Quick facts

Lead sponsor	Virginia Polytechnic Institute and State University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	30 April 2019
Primary completion	30 December 2021
Estimated completion	11 August 2022
Sites	1 location across United States

Drugs / interventions tested

• Acquire Therapy

Conditions studied

• Microcephaly — all drugs for Microcephaly →
• Hyperkinesis With Developmental Delay — all drugs for Hyperkinesis With Developmental Delay →
• Global Developmental Delay — all drugs for Global Developmental Delay →

Sponsor

Virginia Polytechnic Institute and State University

Who can join

Adults 6 Months to 15, any sex, with Microcephaly or Hyperkinesis With Developmental Delay. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial will consist of a clinical series of up to 50 children with Global Developmental Delay and concomitant microcephaly or hyperkinetic movements. All children will be assessed for psychomotor function using standardized assessments, goal specific assessments, with the potential addition of neuroimaging assessment, prior to and after receiving an intensive burst of neuromotor therapy. The interventional effects will be explored by comparing the pre and post interventional assessments and neuroimaging.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.